In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation

Summary

Data linking the response to antiplatelet therapy with clinical outcomes after angioplasty and stenting for lower extremity artery disease (LEAD) are scarce. Moreover, associations of in vivo and thrombin-inducible platelet activation with the occurrence of adverse events have not been investigated in these patients, so far. We therefore assessed clinical outcomes and on-treatment platelet reactivity by four test systems in 108 patients receiving dual antiplatelet therapy after infrainguinal angioplasty and stenting for LEAD. Further, in vivo and thrombin receptor-activating peptide (TRAP)-6-inducible glycoprotein (GP) IIb/IIIa activation and P-selectin expression were measured as sensitive parameters of platelet activation. The primary endpoint was defined as the composite of atherothrombotic events and target vessel restenosis or reocclusion. Residual platelet reactivity to adenosine diphosphate and arachidonic acid was similar between patients without and with adverse outcomes within two-year follow-up (all p>0.05). Further, the occurrence of clinical endpoints did not differ significantly between patients without and with high on-treatment residual platelet reactivity by all test systems (all p>0.05). In contrast, in vivo and TRAP-6-inducible platelet activation were significantly more pronounced in patients with subsequent adverse events (all p<0.05), and high levels of platelet activation were independent predictors of the primary endpoint (adjusted hazard ratios: 3.5 for high in vivo activated GPIIb/IIIa, 2.9 for high TRAP-6-inducible activated GPIIb/IIIa, 2.3 for high in vivo P-selectin, and 3 for high TRAP-6-inducible P-selectin; all p<0.05). In conclusion, in vivo and protease-activated receptor-1-mediated platelet activation predict two-year clinical outcomes in stable patients undergoing angioplasty and stenting for LEAD.

Keywords

Peripheral arterial disease - angioplasty - stenting - platelet reactivity

• References

• 1 Yusuf S, Zhao F, Mehta SR. et al. Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 2001; 345: 494-502.
• 2 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
• 3 Gremmel T, Steiner S, Seidinger D. et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
• 4 Gremmel T, Steiner S, Seidinger D. et al. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets 2011; 22: 188-195.
• 5 Paniccia R, Antonucci E, Gori AM. et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-1847.
• 6 Chen WH, Lee PY, Ng W. et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126.
• 7 Sibbing D, Morath T, Braun S. et al. Clopidogrel response status assessed with multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
• 8 Marcucci R, Gori AM, Paniccia R. et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to adp detected by a point-of-care assay: A 12-month follow-up. Circulation 2009; 119: 237-242.
• 9 Siller-Matula JM, Delle-Karth G, Christ G. et al. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol 2012; 167: 430-435.
• 10 Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
• 11 Gremmel T, Kopp CW, Seidinger D. et al. Preserved thrombin inducible platelet activation in thienopyridine-treated patients. Eur J Clin Invest 2013; 43: 689-697.
• 12 Gremmel T, Kopp CW, Seidinger D. et al. Impact of diabetes on platelet activation in different manifestations of atherosclerosis. Swiss Med Wkly 2013; 143: 0.
• 13 Mani H, Kirchmayr K, Klaffling C. et al. Influence of blood collection techniques on platelet function. Platelets 2004; 15: 315-318.
• 14 Linnemann B, Schwonberg J, Mani H. et al. Standardization of light transmit-tance aggregometry for monitoring antiplatelet therapy: An adjustment for platelet count is not necessary. J Thromb Haemost 2008; 6: 677-683.
• 15 Siller-Matula JM, Panzer S, Jilma B. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. Platelets 2008; 19: 551-554.
• 16 Gremmel T, Eslam RB, Koppensteiner R. et al. Prasugrel reduces agonists’ indu-cible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. Cardiovasc Ther 2013; e40-45.
• 17 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
• 18 Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thromb Hae-most 2011; 106: 211-218.
• 19 Gremmel T, Steiner S, Seidinger D. et al. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res 2011; 128: 352-357.
• 20 Spiliopoulos S, Pastromas G, Katsanos K. et al. Platelet responsiveness to clopi-dogrel treatment after peripheral endovascular procedures - the preclop study: Clinical impact and optimal cut-off value of high on treatment platelet reactivity. J Am Coll Cardiol 2013; 61: 2428-2434.
• 21 Michelson AD, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface p-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
• 22 Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-2361.
• 23 Bonaca MP, Scirica BM, Creager MA. et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 2013; 127: 1522-1529.
• 24 Welten GM, Schouten O, Hoeks SE. et al. Long-term prognosis of patients with peripheral arterial disease: A comparison in patients with coronary artery disease. J Am Coll Cardiol 2008; 51: 1588-1596.